Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD +2.51%21 EV-to-EBITDA is 22.29 as of Aug. 09, 2026, which is 215% above its 10-year median of 7.07. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 99 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 87.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cellyan Biotechnology Co's enterprise value is $9.61 Mil.
Cellyan Biotechnology Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $0.43 Mil. Therefore, Cellyan Biotechnology Co's EV-to-EBITDA for today is 22.29.
The historical rank and industry rank for Cellyan Biotechnology Co's EV-to-EBITDA or its related term are showing as below:
HKPD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.53 Med: 7.07 Max: 22.29
Current: 22.29
During the past 3 years, the highest EV-to-EBITDA of Cellyan Biotechnology Co was 22.29. The lowest was 2.53. And the median was 7.07.
HKPD's EV-to-EBITDA is ranked worse than 87.88% of 99
companies
in the Medical Distribution industry
Industry Median: 8.68
vs HKPD: 22.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cellyan Biotechnology Co (NAS:HKPD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cellyan Biotechnology Co's PE Ratio (TTM) for today is calculated as:
Cellyan Biotechnology Co's share price for today is $0.4176.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cellyan Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.064.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cellyan Biotechnology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's EV-to-EBITDA falls into.
Cellyan Biotechnology Co's current Enterprise Value is $9.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cellyan Biotechnology Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $0.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a EV-to-EBITDA of 22.29 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cellyan Biotechnology Co. This is 215% above median its historical median of 7.07. Over the past decade, Cellyan Biotechnology Co's EV-to-EBITDA has ranged from 2.53 to 22.29. According to the industry distribution chart, Cellyan Biotechnology Co ranks #87 out of 99 companies in the Medical Distribution industry, placing it in the top 87.9%.
Is Cellyan Biotechnology Co's EV-to-EBITDA too high?
Cellyan Biotechnology Co's current EV-to-EBITDA of 22.29 is 215% above median its 10-year median of 7.07. Over the past 10 years, this metric has ranged from a low of 2.53 to a high of 22.29. The Medical Distribution industry median EV-to-EBITDA is 8.68. Cellyan Biotechnology Co's value of 22.29 is 156.8% above this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #87 out of 99 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's EV-to-EBITDA compare to MEDS and COSM?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #87 out of 99 companies for EV-to-EBITDA. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median EV-to-EBITDA is 8.68. Cellyan Biotechnology Co's value of 22.29 is 156.8% above this benchmark. Historically, Cellyan Biotechnology Co's own EV-to-EBITDA has ranged from 2.53 to 22.29 over the past decade. While the company's 10-year median is 7.07 vs. the industry median of 8.68, Cellyan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.68, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current EV-to-EBITDA of 22.29 is 156.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cellyan Biotechnology Co. For the Medical Distribution industry, the median EV-to-EBITDA is 8.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current EV-to-EBITDA is 22.29, which is 215% above median its own 10-year median of 7.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current EV-to-EBITDA of 22.29. The current EV-to-EBITDA is 22.29, which is 215% above median its 10-year median of 7.07 and 156.8% above the Medical Distribution industry median of 8.68. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current EV-to-EBITDA is 22.29 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
